Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib/Chemotherapy in Advanced Thyroid Cancer
NCT04731740Phase 2Withdrawn
- Sponsor
- Saint Petersburg State University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in anaplastic thyroid cancer (ATC), Poorly differentiated thyroid cancer (PDTC), sponsored by Saint Petersburg State University. Planned start Dec 2020; status: withdrawn.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)Poorly differentiated thyroid cancer (PDTC)
Beyond the preview
Go deeper on NCT04731740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731740.